



## Evaluation of Coexistent Pathology in Patients with Breast Cancer Who Underwent Modified Radical Mastectomy (MRM) in Rasool-e- Akram Hospital between Years 2008-2014

Dina Rajabi far, Hamid reza Alizadeh otaghvar, Hamid reza Baradaran and Arefeh Zavari\*

Department of Breast Surgery, Iran University of Medical Science, Iran

### Abstract

**Introduction:** Breast cancer is one of the most important and frequent cancer in women which increase in developing countries. It becomes major cause of death in women between ages 20-59 years. The most prevalent malignant tumor is Invasive Ductal Carcinoma (IDC). Pathology reports play an important role in diagnosis, prognosis and treatment of patients. So, we decided to evaluate the prevalence of coexistent pathology in patients with breast cancer who underwent MRM surgery.

**Methods and Materials:** We study all patients who underwent MRM surgery between years 2008-2014 in Rasool-e-Akram hospital. We evaluate electronic documents and pathology reports of patients and analyze all variants in spss v.18 software.

**Results:** We have 72 cases which 2 of them are men and the rest are women. The mean age is 50.56 year. (Min=27 yrs, max= 86 yrs). The main pathologies are IDC, DCIS, ILC, LCIS, Tubulolobular Carcinoma and the most prevalent one is IDC. In 61.1% of patients, coexistent pathology is reported and the most prevalent one is Fibrocystic changes (84.1%). The other coexistence pathologies are: Ductal Hyperplasia (31.8%), Adenosis (20.5%), Intraductal Papilloma (6.8%), Fibroadenomatoid changes (6.8%), Stromal Fibrosis (4.5%), Columnar changes (2.3%), Apocrine Metaplasia (2.3%), Hypersecretory hyperplasia (2.3%), Lobular Hyperplasia (2.3%), Adenomyoepitheliomatosis (2.3%). There is no significant correlation between main pathology and presence of coexistent pathology. (Sig =0.47).

**Conclusion:** Overlay, the most prevalent main pathology is IDC and Coexistent pathology is fibrocystic changes. There is no significant relation between main pathology and coexistent pathology.

### Introduction

Breast cancer is the most common malignant cancer and also important factor of mortality rate between the women all over the world that contains 9/22% of women's cancer [1-3]. Recently the prevalence of the breast cancer is rising in the developing countries such as Iran [4]. According to the report stated from Iran International cancer department 6976 person had breast. cancer in 2007 (Iv) the common malignant tumor of the breast are :Ductal carcinoma in situ (DCIS) Lobular carcinoma *in situ*, Invasive ductal carcinoma colloid carcinoma and tubular invasive carcinoma medullary colloid carcinoma and tubular carcinoma and according to this kind of tumors the way of treatment is so different such as Radical microscopy, radiotherapy hormone therapy and etc. [5]. It's important to consider that final decision for stages of treatment and disease is according to pathologic recording [6,7] the type of mass and pathology is important so that in researches the present of lobular neoplasia with invaver breast tumor play an important roie in pre awareness and increases the risk of tumor recurrent of the breast [8-10] also the present of proliferative toll in invasive breast cancer is not rare and happens until 23% [11] for this reasons and according to high prevalence of infecting breast cancer and its mortality rate and its important of pathologic findings getting tolls in pre awareness we are going to study the type of pathologic tolls with malignant breast tumors in patient under treating with radical mastoscopy between the year 1386-1393 in Rasool Akram hospital in this article [12-17].

### OPEN ACCESS

#### \*Correspondence:

Arefeh Zavari, Department of Breast Surgery, Iran University of Medical Science, Iran,  
E-mail: zavari.hd@gmail.com

Received Date: 05 Dec 2016

Accepted Date: 27 Feb 2017

Published Date: 06 Mar 2017

#### Citation:

Dina Rajabi far, Hamid reza Alizadeh otaghvar, Hamid reza Baradaran, Arefeh Zavari. Evaluation of Coexistent Pathology in Patients with Breast Cancer Who Underwent Modified Radical Mastectomy (MRM) in Rasool-e- Akram Hospital between Years 2008-2014. *Clin Surg.* 2017; 2: 1343.

Copyright © 2017 Arefeh Zavari. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Method and Material

In this study we administered a list of people who were under the mild radical mastoscopy between the year 2008-2014 in Rasool Akram hospital. Then the needed variable was reduced from their electronic files. This getting information was analysed with spss software. We used ANOVA, correlation and chi square for absorebency analysis and some index such as mean, mode and average for descriptive analysis.

## Result

The variable items are main toll pathology, favorable pathology, gender, location of mass, old and blood contention. Study the relation between gender and age and mass location showed that from 72 patient 2 people were men with invasive ductal carcinoma in left breast aged 83 and 84 with no favourable pathology. The average of olds were 50 56. 56% of patient have left breast cancer and 50% of them have right breast cancer the main toll pathology were invasive and in situ ductal carcinoma invasive and in situ lobular carcinoma recorded carcinoma. The most common with 87.3% and in totally 95.7% of patient had ductal carcinoma (both invasive and in situ) and 7% of patient had lobular carcinoma (both invasive and situ). 5.6% was situ ductal carcinoma, 35.2% invasive ductal carcinoma and 50.7% both in situ and invasive ductal carcinoma and 4.2% ductal carcinoma with lobular carcinoma the study between favourable pathology and main toll pathology showed 41.1% of patient (44case) had favourable pathology and 38.9% did not have favourable pathology is fibrocystic changes (84.1%) of patient with favourable pathology and other favourable pathology in order prera lance are ductal hyperplasia (31.8%) adeno sis (20.5%). Interdductal papilloma (6.8%) fibroadenomatoid stromal fibrosis (4.5%) komular changes (2.3%). Apocrine changes (2.3%) hyper secretory hyperplasia (2.3%) adeno epithelium atosis (2.3%) between the main toll pathology and favourable pathology dose not find any relationship. Between fibrocystic (36 cases) and the kind of main toll pathology we do not find any important relationship (sig=0.47).

In our study 80.6 % (58 cases) of patient had not vascular complication and 19.4 % of them have it according to their files. In the analytic studies which we do between the present of fibrocystic changes (36 case) and the type of main pathology of mass there was not any significant relationship (sig=0.87). Also there is not significant relationship between ductal hyperplasia and (13 case) with the main type of pathology (sig=0.48).

There was not any significant relationship between main pathology of mass of patient with vascular complication or non-complication in the study of 14 cases which had vascular complication (sig=0.94). Also there was not any significant relationship between the present of vascular complication and present of other accompanied pathology (sig=0.37). From 37 cases which had fibrocystic changes we showed 5 cases with vascular complication an there was not any significant relationship between the present of relationship and fibrocystic changes (sig=0.30). There was not any relationship between the age of patient and the type of main pathology (sig=0.60). The age average among patient who have vascular complication was 53.5 and it was 49.8 among 58 cases who did not have vascular complication which there was not any significant analytical finding (sig=0/33). Also there was not any relationship between the mass location and age average of patient. The age average of patient who have right breast masses was 48.7 and it was 52.3 in patient who have left breast masses (sig=0.22).

From 72 patient 44 cases had other pathology than main pathology that their age average was 48.4 and we did not find any significant finding between the age of patient and the present of pathology (sig=0.07).

## Discussion

Breast cancer is the most common malignant cancer and cause of mortality because of cancer among women which conform 9.22% of women's cancer and it was the reason of 7.13% of mortality of women in 2008 [18-25]. Breast cancer is the most common reason of death of women all over the world [26-30]. Breast cancer is the rarest cancer in men and conform 0.2% of men's cancer [31,32]. According to studies, the outbreak of breast cancers is increasing among women with 50-64 year old and this matter is happy for screening at this age. This cancer is the main cause of death among women with 20-59 year old [33-35]. In our study the age average of patient was 50-56. In the clinical study of patient the final decision for curing patient and the stage of illness is according to their pathologic files [36,37]. These files are the most important files in the study of illness so that we also use these files for achieving main variables. As we see in the recent searches that the most common pathology among Iranian patient infected with breast cancer is invasive ductal carcinoma, (79%-89%) [38,39].

In our study we find that the most common pathology was invasive ductal carcinoma (87.3%) and in totally 95.7% of patient had ductal carcinoma both in situ and invasive. Also in another studies the most common histologic breast cancer in the sample of breast cancer was invasive ductal carcinoma [40-43]. In our study 7% of patient had lobular masses which according to studies it can be one of the most important factor in pre awareness of mass recurrences in the same breast [43-49]. In the other hand in one study at 2009 in Sweden the present of both LCIS and DCIS was recommended as one of the factor for mass recurrences which this matter was showed in 4.2% of our cases [50-55]. In the study of attendant pathology 6.1% of patient have one attendant pathology at least which their most common was fibrocystic changes (84.1%) which is most common benign tolls among women according to recent studies which exist in 60-90% of normal biopsies and it is estimated that 10% of women (at least) are infecting with cystic illness with clinical signs all over their life [56,57]. Considering that this study is cross sectional we cannot opine about the discipline of these tolls and also we cannot consider these tolls as a pre awareness or a risk factor but according to analytical study which we do there was not any significant finding between the type of main pathology and fibrocystic changes (sig=0.87). Second attendant pathology according to amplitude was ductal hyperplasia (31.8%) which can be a risk factor for tumor recurrences in the same breast or aliem breast [58-60]. But in another researches showed that there is not any significant relationship between the present of ductal carcinoma in the same breast [61]. And we did not do anything for finding relationship between these tolls, also we did not find any relationship between main pathology and ductal hyperplasia (13 cases) in our analytical studies (sig=0.48). Other attendant pathologies according to outbreak are: adenosis (20.5%) inters ductal papilloma (6.8%) fibroadenomatoid changes (6.8%), stromal fibros (5.4%), komular changes (2.3%), apocrine metaplasia (2.3%), hyper scrotory hyperplasia (2.3%), lobular hyperplasia (2.3%), and adenoepitheliomatosis (2.3%). In one of the case report in 2013 in Tuness we can see second grade infected ductal carcinoma and lobular mastit in 77-year old women which this camaraderie was not in any of our patient. In another case-report in 2014 we

can see fibroadenomatoid changes and inter ductal carcinoma at the same time also we can see fibroadenomatoid changes with main pathology in 3 cases (6.8%). According to recent studies the present of proliferativ tolls in invasive and non invasive breast cancers was rare and it is happening until 23% and we see attendant pathology in 61.1% of our patient.

## References

- Anderson WF SC, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). *Breast Dis.* 2005; 22: 9-23.
- Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. *Oncologist* 2004; 9: 606-616.
- Bertucci F, Lagarde A, Ferrari A, Finetti P, Charafe Jauffret E, Van Laere S, et al. 8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. *PloS one.* 2012; 7: e37943.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin.* 2013; 63: 11-30.
- Kelsey JL. A review of the epidemiology of human breast cancer. *Epidemiologic Reviews.*1979; 1: 74-109
- Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. *Epidemiol Rev.* 1993; 15: 7-16.
- M Y, Ahmadi M R H, J K, H P, K H A, M R Y, K H. An 8 years retrospective study of breast cancer incidence in ilam province, Western iran. *J Clin Diagn Res.* 2013; 7: 2923-2925.
- Afsharfard A, Orang E, Tahmasbpour E. Trends in epidemiology, clinical and Histopathological Characteristics of breast cancer in Iran: results of a 17 year study. *Asian Pacific J Cancer Prev.* 2013; 14: 6905-6911.
- Ziaei JE, Sanaat Z, Asvadi I, Dastgiri S, Pourzand A, Vaez J. Survival analysis of breast cancer patients in northwest Iran. *Asian Pac J Cancer Prev.* 2013; 14: 39-42.
- Harirchi I, Karbakhsh M, Kashefi A, Momtahan AJ. Breast-cancer in Iran: Results of a Multi-center study. *Asian Pacific J Cancer Prev.* 2004; 5: 24-27.
- Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast Cancer in Iran: An Epidemiological Review. *Breast J.* 2007; 13: 383-391.
- Sirous M. [The epidemiology of breast masses among women in Esfahan]. *Iran J Surg.* 2008;16: 51-56.
- Harirchi I, Karbakhsh M, Kashefi A, Momtahan AJ. Breast cancer in Iran: results of a multi-center study. *Asian Pac J Cancer Prev.* 2004; 5: 24-27.
- Talaieazadeh A, Tabesh H, Sattari A, Ebrahimi S. Cancer incidence in southwest of iran: first report from huzestan population-based cancer registry2002-2009. *Asian Pac J Cancer Prev.* 2013; 14: 7517-7522.
- Mousavi SM, Mohagheghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z. Outcome of Breast Cancer in Iran: A Study of Tehran Cancer Registry Data. *Asian Pac J Cancer Prev.* 2008; 9: 275-278.
- I Harirchi, M Ebrahimi, N Zamani,SJarvandi, A Montazeri. Breast cancer in Iran: a review of 903 case records. *Public Health.* 2000; 114: 143-145.
- Movahedi M, Haghight S, Khayamzadeh, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in iran, a national study. *Iran Red Crescent Med J.* 2012; 14: 798-804.
- Hosseini MS, Arab M, Nemat Honar B, Noghabaei G, Safaei N, Ghasemi T, et al. Age - specific incidence rate change at breast Cancer and its different histopathologic subtypes in Iran and Western countries. *Pak J Med Sci.* 2013; 29: 1354-1357.
- Yue Chen, Wendy Thompson, Robert Semenciw, Yang Mao. Epidemiology of Contralateral Breast Cancer. *Cancer Epidemiol Biomarkers Prev.* 1999; 885; 8.
- Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med.* 2002; 347: 1227-1232.
- Edge SB. American joint committee on cancer staging manual. 7th ed. New York, Springer. 2010.
- Brunnicardi F. Schwartz's principles of surgery, 9th ed. New York, McGraw-Hill. 2010.
- Mostafa Hosseini Adnan Tizmaghz, Hamidreza AlizadehOtaghvar, Marjan Shams. The prevalence of fibrocystic changes of breast tissue of patients who underwent reduction mammoplasty in Rasool-Akram, Firuzgar and Sadr Hospitals during Rasool-Akram, Firuzgar and Sadr Hospitals during2007-2012. *Advances in Surgical Sciences* 2014; 2: 5-8.
- Soleymanzadeh P, Hosseini M, Esmaeili SK, Alizadeh-otaghvar H. Primary breast angiosarcoma associated with abnormalities in international normalized ratio platelet count and anemia. *J Cancer Res Ther.* 2015; 11: 655.
- Sasson AR, Fowble B, Hanlon AL, Torosian MH, Freedman G, Boraas M, et al. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. *Cancer.* 2001; 91: 1862-1869.
- Rudloff U, Brogi E, Brockway JP, Goldberg JJ, Cranor M, Wynveen CA, et al. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. *Cancer.* 2009; 115: 1203-1214.
- Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, et al Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinomarecurrence and contralateral breast carcinoma development in patients with ductal carcinomain situ treated with breast-conserving therapy. *Cancer.* 2006; 106: 42-50.
- Moran M, Haffty BG. Lobular carcinoma in situ as a component of breast cancer: the long-term outcome in patients treated with breast-conservation therapy. *Int J Radiat Oncol Biol Phys.* 1998; 40: 353-358.
- Abner AL, Connolly JL, Recht A, Bornstein B, Nixon A, Hetelekidis S, et al. The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. *Cancer.* 2000; 88: 1072-1077.
- Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. *Breast Cancer Res Treat.* 2000; 62: 197-210.
- Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, et al. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. *Cancer.* 2006; 106: 42-50.
- Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. *Cancer.* 1985; 55: 2698-2708.
- Bodian CA, Perzin KH, Lattes R, Hoffman P, Abernathy TG. Prognostic significance of benign proliferative breast disease. *Cancer.* 1993; 71: 3896-3907.
- London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. *JAMA.* 1992; 267: 941-944.
- Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk and associated with proliferative breast disease and atypical hyperplasia. *Cancer.* 1993; 71: 1258-1265.
- Shaaban AM, Sloane JP, West CR, Moore FR, Jarvis CF, Williams EM, et al. Histopathologic types of benign breast lesions and the risk of breast cancer. *Am J Surg Pathol.* 2002; 26: 421-430.

37. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. *Cancer Epidemiol Biomarkers Prev.* 1997; 6: 297-301.
38. Jain S, Kaur R, Agarwal R, Chopra P. Bilateral Invasive Duct Carcinoma, Phyllodes Tumor and Multiple Fibroadenomas of Breast Associated with Lymph Node Metastases - Rare Coexistence. *Indian J Surg Oncol.* 2014; 5:186-188.
39. Limaïem F, Khadhar A, Hassan F, Bouraoui S, Lahmar A, Mzabi S. Coexistence of lobular granulomatous mastitis and ductal carcinoma: a fortuitous association? *Pathologica.* 2013; 105: 357-360.
40. Mechera R, Viehl CT, Oertli D. Factors predicting in-breast tumor recurrence after breast-conserving surgery. *Breast Cancer Res Treat.* 2009; 116: 171-177.
41. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. *Cancer.* 2004; 101: 1977-1986.
42. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes J. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study. *Pathology.* 2004; 36: 221-229.
43. Greenfield LJ. *Surgery Scientific Principles and Practice.* 3rd ed. USA, Lippincott-Raven, 2004; 1357-1415.
44. Ackermans RJ. *Surgical Pathology.* 9th ed. USA, Mosby, 2004; 1802-1803.
45. Iglehart JD, Kaelin C. Disease of the Breast. In: Townsend C M, Beauchamp R D, Evers B M. *Mattox k l. Sabiston text book of surgery, sixteenth edition,* W.B. Saunders Company, Philadelphia, 2001. 555-591.
46. Bland KI, vezeridis MP, Copeland IM. Breast. In: Schwarts S I, Shires G T. Spencer F C, Daly J M, Fischer J E, Galloway A C. *Principles of Surgery,* Seventh edition, M C Grow- Hill Company, New york, 1999; 533-601.
47. Morrow M. Breast. In: Greenfield I j, Mulholland MW, Oldham KT, Zelenock GB, Lillemoe KD. *Surgery Scientific Principles and practice.* Third edition. Lippincott Willams and Wilkins, Philadelphia, 2001; 1334-1373.
48. Haagensen CD. *Diseases of the breast* 3rd Ed. Philadelphia W.B Saunders. 1986; 31-53.
49. Schnitt SJ, Connolly JL. Pathology of benign breast disorders. In: Harris JR, Lippman ME, Morrow ME. *Diseases of the Breast.* Philadelphia. Lippincott- Raven, 1996; 27-42.
50. Harris J R, Lippman M E, Morrow M. *Disease of the breast.* Philadelphia. Lippincott – Raven. 1996; 1047: 24-43.
51. Landis SH, Murray T, Bolden SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. *CA Cancer J Clin.* 1999; 49: 8-31.
52. Morrow M, Wong S, Venta L, The evaluation of breast masses in woman younger than forty years of age, *Surgery.* 1998; 124: 634-641.
53. Steinbrunn BS, Zera RT, Rodriguez RL. Mastalgia. Tailoring treatment the breast pain. *Postgrad Med.* 1997; 120: 153-154.
54. Iglehart DJ, Kaelin CM. Breast, in: Courtney M, Townsend JR, editors. *Sabiston textbook of surgery.* 6th ed. Philadelphia: W.B. Saunders. 2001; 2: 560.
55. Berek JS, Hillard PA, Adashi EY. *Novak's Gynecology.* 15<sup>th</sup> ed. Baltimore, Williams & Wilkins, 2006; 833-852.
56. Eley JW, Hill HA, Chen VW. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. *JAMA.* 1994; 272: 947-954.
57. Marie Gethins. Breast Cancer in Men. *JNCI J Natl Cancer Inst.* 2012; 104: 436-438.
58. Giordano SH, Buzdar AU, Hortobagyi GN. Breast Cancer in Men. *Ann Intern Med.* 2002; 137: 678-687.
59. William L Donegan, Philip N. Redlich. Breast Cancer in Men. *Surgical Clinics of North America.* 1996, 2: 343-363.
60. Spatz MW. Breast cancer in men. *Am Fam Physician.* 1988; 38: 187-189.
61. K McPherson, C M Steel, J M Dixon. Breast cancer-epidemiology, risk factors, and genetics. *BMJ.* 2000; 321: 1198.